Genmab | GEN - PE Price to Earnings


Genmab reported 16.04 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
Agios Pharmaceuticals 3.56 0 Mar/2026
Almirall 79.43 0.3 Dec/2025
Amarin 91.05 88.3 Jun/2023
Amgen 18.07 1.77 Jun/2026
argenx SE 35.53 3.41 Jun/2026
AstraZeneca 25.34 4.25 Jun/2026
Bayer 4.14 0.74 Jun/2026
BioMarin Pharmaceutical 21.07 5.79 Jun/2026
Demant 27.46 7.1 Dec/2025
Exelixis 18.02 4.11 Jun/2026
Fresenius Medical Care 12.13 5.49 Jun/2026
Genmab 16.04 1.05 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
GN Store Nord 9.38 1.39 Jun/2026
GRIFOLS 14.71 3.73 Jun/2026
Hikma Pharmaceutical 10.43 3.72 Dec/2025
Lakefront Biotherapeutics 2.68 0.14 Jun/2026
Lonza 34.34 2.58 Dec/2025
Merck 17.21 4.47 Jun/2026
Novartis 22.41 2.24 Jun/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 18.96 7.12 Jun/2026
UCB 29.7 5.52 Dec/2025